| 自体造血干细胞移植治疗恶性淋巴瘤40例临床疗效分析 |
| 投稿时间：2017-03-23 修订日期：2017-05-04 点此下载全文 |
| 引用本文：张奉齐,王季石,吴莉,卢英豪.自体造血干细胞移植治疗恶性淋巴瘤40例临床疗效分析[J].医学研究杂志,2018,47(1):57-61 |
| DOI：
10.11969/j.issn.1673-548X.2018.01.015 |
| 摘要点击次数: 1148 |
| 全文下载次数: 818 |
|
| 基金项目:国家自然科学基金资助项目（81270636）；贵州省科技厅基金资助项目[筑科合同（2012103）26号] |
|
| 中文摘要:目的 探讨大剂量化疗联合自体造血干细胞移植（high dose therapy/autologous hematopoietic stem cell transplantation，HDT/AHSCT）在恶性淋巴瘤治疗中的临床疗效。方法 选择2011年11月~2016年11月于笔者医院接受HDT/AHSCT治疗的的40例恶性淋巴瘤患者的病历资料。其中男性26例，女性14例，中位年龄为32（9~61）岁。非霍奇金淋巴瘤34例，霍奇金淋巴瘤6例。预处理方案为BEAM方案23例，BEAC方案10例，CBV方案7例。结果 所有患者均采集到足够的外周血造血干细胞，且均成功获得造血重建。其中白细胞植活的中位时间为10（9~16）天；血小板植活的中位时间为13（9~29）天。所有患者均未发生移植相关死亡，移植前的完全缓解（CR）率为75%，部分缓解（PR）率为25%；移植后的CR率为95%，PR率为5%。中位随访21（2~60）个月，预期2年及3年的总生存率（OS）分别为81.8%及71.2%，2年及3年的无进展生存率（PFS）分别为72.2%和43.4%。其中27例（67.5%）患者存活，13例（32.5%）患者死亡。结论 HDT/AHSCT有造血重建快、并发症少、安全有效等优点，可作为治疗恶性淋巴瘤患者安全、有效的方法。 |
| 中文关键词:大剂量化疗联合自体造血干细胞移植 恶性淋巴瘤 疗效 |
| |
| Clinical Treatment of Malignant Lymphoma by Autologous Hematopoietic Stem Cell Transplantation in 40 Patients |
|
|
| Abstract:Objective To investigate the clinical efficacy of malignant lymphoma by high-dose therapy/autologous hematopoietic stem cell transplantation (HDT/AHSCT). Methods Forty patients with malignant lymphoma were treated by HDT/AHSCT from November 2011 to November 2016 in our hospital. There were 26 males and 14 females. The median age was 32 (9-61) years old. 6 patients with HL and 34 patients with NHL. Conditioning regiment was BEAM in 23 cases, BEAC in 10 cases, CBV in 7 cases. Results Adequate peripheral blood stem cells were collected. And a total of 40 patients achieved hematopoietic reconstruction successfully. The median time to neutrophil engraftment was at day 10(range, 9-16 days). Platelet engraftment occurred on median day 13 (range,9-29 days) respectively. There was no transplant-related deaths occurred in all patients. The rate of CR before transplantation was 75% and the rate of PR was 25%. The rate of CR after transplantation was 95%. The median follow-up time was 21 (2-60) months, 2 and 3 years PFS was 72.2%/43.4%. 2 and 3 years OS was 81.8%/71.2%. 27 patients (67.5%) were survived, and 13 patients (32.5%) were dead (10patients died of recurrence). Conclusion HDT/AHSCT has advantages of rapid hematopoietic reconstitution, less complications, safety and efficiency. It can be used as safe and effective method for the treatment of malignant lymphoma. |
| keywords:High-dose therapy/autologous hematopoietic stem cell transplantation Malignant lymphoma Clinical efficacy |
| 查看全文 查看/发表评论 下载PDF阅读器 |
